{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:45:04Z","timestamp":1792827904815,"version":"4.5.0"},"reference-count":146,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Platelets have been hypothesized to promote certain neoplastic malignancies; however, antiplatelet drugs are still not part of routine pharmacological cancer prevention and treatment protocols. Paracrine interactions between platelets and cancer cells have been implicated in potentiating the dissemination, survival within the circulation, and extravasation of cancer cells at distant sites of metastasis. Signals from platelets have also been suggested to confer epigenetic alterations, including upregulating oncoproteins in circulating tumor cells, and secretion of potent growth factors may play roles in promoting mitogenesis, angiogenesis, and metastatic outgrowth. Thrombocytosis remains a marker of poor prognosis in patients with solid tumors. Experimental data suggest that lowering of platelet count may reduce tumor growth and metastasis. On the basis of the mechanisms by which platelets could contribute to cancer growth and metastasis, it is conceivable that drugs reducing platelet count or platelet activation might attenuate cancer progression and improve outcomes. We will review select pharmacological approaches that inhibit platelets and may affect cancer development and propagation. We begin by presenting an overview of clinical cancer prevention and outcome studies with low-dose aspirin. We then review current nonclinical development of drugs targeted to platelet binding, activation, and count as potential mitigating agents in cancer.<\/jats:p>","DOI":"10.1182\/blood.2019003977","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T17:26:19Z","timestamp":1620062779000},"page":"3201-3211","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":117,"title":["Aspirin and antiplatelet treatments in cancer"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-0259","authenticated-orcid":false,"given":"Derrick L.","family":"Tao","sequence":"first","affiliation":[{"name":"Division of Hematology & Medical Oncology,"},{"name":"Department of Biomedical Engineering, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3631-2156","authenticated-orcid":false,"given":"Samuel","family":"Tassi Yunga","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, and"},{"name":"Cancer Early Detection & Advanced Research Center, Oregon Health & Science University, Portland, OR; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-1612","authenticated-orcid":false,"given":"Craig D.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9481-0124","authenticated-orcid":false,"given":"Owen J. T.","family":"McCarty","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology,"},{"name":"Department of Biomedical Engineering, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"12","key":"2021062208221218600_B1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2159-8290.CD-12-0216","article-title":"Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells","volume":"2","author":"Kuznetsov","year":"2012","journal-title":"Cancer Discov"},{"issue":"5","key":"2021062208221218600_B2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"issue":"30","key":"2021062208221218600_B3","doi-asserted-by":"crossref","first-page":"E3053","DOI":"10.1073\/pnas.1411082111","article-title":"Platelets guide the formation of early metastatic niches","volume":"111","author":"Labelle","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2021062208221218600_B4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V96.5.1789","article-title":"Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions","volume":"96","author":"McCarty","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2021062208221218600_B5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","article-title":"Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells","volume":"72","author":"Placke","year":"2012","journal-title":"Cancer Res"},{"issue":"6024","key":"2021062208221218600_B6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"issue":"2","key":"2021062208221218600_B7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"2021062208221218600_B8","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-derived transforming growth factor-\u03b2 down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"2021062208221218600_B9","first-page":"1295","article-title":"Lysis of tumor cells by natural killer cells in mice is impeded by platelets","volume":"59","author":"Nieswandt","year":"1999","journal-title":"Cancer Res"},{"issue":"1","key":"2021062208221218600_B10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","article-title":"Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells","volume":"105","author":"Palumbo","year":"2005","journal-title":"Blood"},{"key":"2021062208221218600_B11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fonc.2014.00245","article-title":"Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1","volume":"4","author":"Amo","year":"2014","journal-title":"Front Oncol"},{"issue":"4","key":"2021062208221218600_B12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.1994.tb06736.x","article-title":"Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets","volume":"87","author":"Boukerche","year":"1994","journal-title":"Br J Haematol"},{"issue":"5","key":"2021062208221218600_B13","first-page":"298","article-title":"Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues","volume":"9","author":"Grignani","year":"1989","journal-title":"Invasion Metastasis"},{"issue":"12","key":"2021062208221218600_B14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01209121","article-title":"Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines","volume":"122","author":"Heinm\u00f6ller","year":"1996","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"2021062208221218600_B15","first-page":"541","article-title":"Human tumor cells cultured \u201cin vitro\u201d activate platelet function by producing ADP or thrombin","volume":"74","author":"Zucchella","year":"1989","journal-title":"Haematologica"},{"issue":"36","key":"2021062208221218600_B16","doi-asserted-by":"crossref","first-page":"25993","DOI":"10.1074\/jbc.M702327200","article-title":"Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells","volume":"282","author":"Suzuki-Inoue","year":"2007","journal-title":"J Biol Chem"},{"issue":"9","key":"2021062208221218600_B17","first-page":"2396","article-title":"Increased synthesis of prostacyclin and thromboxane in human ovarian malignancy","volume":"48","author":"Aitokallio-Tallberg","year":"1988","journal-title":"Cancer Res"},{"issue":"1","key":"2021062208221218600_B18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.2014.271","article-title":"Molecular targets of aspirin and cancer prevention","volume":"111","author":"Alfonso","year":"2014","journal-title":"Br J Cancer"},{"issue":"7","key":"2021062208221218600_B19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/jso.23163","article-title":"Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer","volume":"106","author":"Ishizuka","year":"2012","journal-title":"J Surg Oncol"},{"issue":"9","key":"2021062208221218600_B20","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1183\/09031936.96.09091826","article-title":"Prognostic significance of thrombocytosis in patients with primary lung cancer","volume":"9","author":"Pedersen","year":"1996","journal-title":"Eur Respir J"},{"issue":"7","key":"2021062208221218600_B21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic thrombocytosis in ovarian cancer [published correction appears in N Engl J Med. 2012;367(18):1768]","volume":"366","author":"Stone","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2021062208221218600_B22","doi-asserted-by":"crossref","first-page":"023001","DOI":"10.1088\/2057-1739\/aa6c05","article-title":"Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer","volume":"3","author":"Sylman","year":"2017","journal-title":"Converg Sci Phys Oncol"},{"issue":"6","key":"2021062208221218600_B23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1055\/s-0037-1613413","article-title":"Impact of pretreatment thrombocytosis on survival in primary breast cancer","volume":"89","author":"Taucher","year":"2003","journal-title":"Thromb Haemost"},{"issue":"5","key":"2021062208221218600_B24","first-page":"1954","article-title":"Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment","volume":"41","author":"Narisawa","year":"1981","journal-title":"Cancer Res"},{"issue":"1","key":"2021062208221218600_B25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3835(83)90082-4","article-title":"The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat","volume":"21","author":"Pollard","year":"1983","journal-title":"Cancer Lett"},{"issue":"15","key":"2021062208221218600_B26","first-page":"4399","article-title":"Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study","volume":"48","author":"Kune","year":"1988","journal-title":"Cancer Res"},{"issue":"6710","key":"2021062208221218600_B27","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/bmj.299.6710.1247","article-title":"Aspirin use and chronic diseases: a cohort study of the elderly","volume":"299","author":"Paganini-Hill","year":"1989","journal-title":"BMJ"},{"issue":"23","key":"2021062208221218600_B28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199112053252301","article-title":"Aspirin use and reduced risk of fatal colon cancer","volume":"325","author":"Thun","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"2021062208221218600_B44","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2021062208221218600_B144","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2007.10.014","article-title":"Aspirin and folic acid for the prevention of recurrent colorectal adenomas","volume":"134","author":"Logan","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"2021062208221218600_B145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Ann Intern Med"},{"issue":"16","key":"2021062208221218600_B146","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"issue":"10152","key":"2021062208221218600_B57","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"2021062208221218600_B54","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2021062208221218600_B29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","article-title":"Aspirin: a historical and contemporary therapeutic overview","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"2021062208221218600_B30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","article-title":"Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention","volume":"36","author":"Ornelas","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"2021062208221218600_B31","doi-asserted-by":"crossref","first-page":"C176","DOI":"10.1152\/ajpcell.00196.2016","article-title":"Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC","volume":"312","author":"Mitrugno","year":"2017","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"2021062208221218600_B32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1073\/pnas.95.2.681","article-title":"Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis","volume":"95","author":"Chan","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2021062208221218600_B33","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1182\/blood-2006-07-038539","article-title":"Moderation of the platelet releasate response by aspirin","volume":"109","author":"Coppinger","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2021062208221218600_B34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1042\/BST20140322","article-title":"Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk","volume":"43","author":"Dovizio","year":"2015","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"2021062208221218600_B35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bph.12250","article-title":"Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin","volume":"170","author":"Etulain","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"12","key":"2021062208221218600_B36","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1096\/fj.201600530R","article-title":"Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1","volume":"30","author":"Rauzi","year":"2016","journal-title":"FASEB J"},{"issue":"6","key":"2021062208221218600_B37","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.31557\/APJCP.2019.20.6.1675","article-title":"Over-expression of cyclooxygenase-2 in colorectal cancer patients","volume":"20","author":"Negi","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"25","key":"2021062208221218600_B38","doi-asserted-by":"crossref","first-page":"21353","DOI":"10.18632\/oncotarget.3860","article-title":"Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer","volume":"6","author":"Wilson","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2021062208221218600_B39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/1534735406291499","article-title":"Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy","volume":"5","author":"McCarty","year":"2006","journal-title":"Integr Cancer Ther"},{"issue":"6","key":"2021062208221218600_B40","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.cellsig.2008.02.004","article-title":"Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras\/c-Raf interaction and activation of MAP kinase phosphatases","volume":"20","author":"Pan","year":"2008","journal-title":"Cell Signal"},{"issue":"8","key":"2021062208221218600_B41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/09537104.2017.1416076","article-title":"Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug","volume":"29","author":"Mitrugno","year":"2018","journal-title":"Platelets"},{"issue":"12","key":"2021062208221218600_B42","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/M15-2117","article-title":"Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force","volume":"164","author":"Chubak","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"2021062208221218600_B43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH775>3.0.CO;2-K","article-title":"Validation of a model of colon cancer progression [published correction appears in J Pathol. 2001;194(4):507]","volume":"192","author":"Hewitt","year":"2000","journal-title":"J Pathol"},{"issue":"10","key":"2021062208221218600_B45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"2021062208221218600_B46","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJMp030005","article-title":"Aspirin and the prevention of colorectal cancer","volume":"348","author":"Imperiale","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"2021062208221218600_B47","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/jnci\/85.15.1220","article-title":"Low-dose aspirin and incidence of colorectal tumors in a randomized trial","volume":"85","author":"Gann","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2021062208221218600_B48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.294.1.47","article-title":"Low-dose aspirin in the primary prevention of cancer: the Women\u2019s Health Study: a randomized controlled trial","volume":"294","author":"Cook","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"2021062208221218600_B49","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.294.8.914","article-title":"Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer","volume":"294","author":"Chan","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"2021062208221218600_B50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-146-5-200703060-00008","article-title":"Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"146","author":"U.S. Preventive Services Task Force","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9754","key":"2021062208221218600_B51","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"9826","key":"2021062208221218600_B52","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"2021062208221218600_B53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.gastro.2015.11.018","article-title":"Where do we stand with aspirin for the prevention of colorectal cancer? The USPSTF recommendations","volume":"150","author":"Chan","year":"2016","journal-title":"Gastroenterology"},{"issue":"16","key":"2021062208221218600_B55","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"2021062208221218600_B56","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"2021062208221218600_B58","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Supplementary appendix, the ASPREE trial","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2021062208221218600_B59","author":"Hennepin Healthcare Research Institute"},{"issue":"10240","key":"2021062208221218600_B60","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"2021062208221218600_B61","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"2021062208221218600_B62","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/cncr.27817","article-title":"Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women\u2019s Health Initiative","volume":"119","author":"Gamba","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"2021062208221218600_B63","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1055-9965.EPI-16-0508","article-title":"Aspirin use and reduced risk of pancreatic cancer","volume":"26","author":"Risch","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2021062208221218600_B64","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12885-018-4156-5","article-title":"Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies","volume":"18","author":"Qiao","year":"2018","journal-title":"BMC Cancer"},{"key":"2021062208221218600_B65","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1745-6215-12-261","article-title":"The utility of aspirin in Dukes C and high risk Dukes B colorectal cancer\u2014the ASCOLT study: study protocol for a randomized controlled trial","volume":"12","author":"Ali","year":"2011","journal-title":"Trials"},{"key":"2021062208221218600_B66","author":"Chen","year":"2019"},{"key":"2021062208221218600_B67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cct.2016.10.004","article-title":"ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours","volume":"51","author":"Coyle","year":"2016","journal-title":"Contemp Clin Trials"},{"issue":"9098","key":"2021062208221218600_B68","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council\u2019s General Practice Research Framework","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"2021062208221218600_B69","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1109\/51.932731","article-title":"Cell-cell interactions in inflammation and cancer metastasis","volume":"20","author":"Burdick","year":"2001","journal-title":"IEEE Eng Med Biol Mag"},{"issue":"12","key":"2021062208221218600_B70","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1096\/fasebj.12.12.1241","article-title":"CD24 mediates rolling of breast carcinoma cells on P-selectin","volume":"12","author":"Aigner","year":"1998","journal-title":"FASEB J"},{"issue":"4","key":"2021062208221218600_B71","doi-asserted-by":"crossref","first-page":"C907","DOI":"10.1152\/ajpcell.00463.2007","article-title":"The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion","volume":"294","author":"Alves","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"2021062208221218600_B72","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12253-012-9531-y","article-title":"Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1","volume":"18","author":"Gong","year":"2012","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"2021062208221218600_B73","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1681\/ASN.2008070782","article-title":"The role of podocalyxin in health and disease","volume":"20","author":"Nielsen","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2021062208221218600_B74","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0006-3495(02)75212-0","article-title":"Fluid shear regulates the kinetics and molecular mechanisms of activation-dependent platelet binding to colon carcinoma cells","volume":"83","author":"McCarty","year":"2002","journal-title":"Biophys J"},{"issue":"12","key":"2021062208221218600_B75","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1074\/jbc.M213233200","article-title":"Single molecule characterization of P-selectin\/ligand binding","volume":"278","author":"Hanley","year":"2003","journal-title":"J Biol Chem"},{"issue":"5","key":"2021062208221218600_B76","doi-asserted-by":"crossref","first-page":"C1223","DOI":"10.1152\/ajpcell.00403.2002","article-title":"Exogenous eosinophil activation converts PSGL-1-dependent binding to CD18-dependent stable adhesion to platelets in shear flow","volume":"284","author":"McCarty","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"2021062208221218600_B77","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbrc.2005.01.146","article-title":"Preferential binding of platelets to monocytes over neutrophils under flow","volume":"329","author":"Ahn","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"2021062208221218600_B78","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/j.1538-7836.2011.04401.x","article-title":"Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin","volume":"9","author":"Kozlowski","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"16","key":"2021062208221218600_B79","doi-asserted-by":"crossref","first-page":"9325","DOI":"10.1073\/pnas.95.16.9325","article-title":"P-selectin deficiency attenuates tumor growth and metastasis","volume":"95","author":"Kim","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2021062208221218600_B80","doi-asserted-by":"crossref","first-page":"e91320","DOI":"10.1371\/journal.pone.0091320","article-title":"P-selectin-mediated platelet adhesion promotes the metastasis of murine melanoma cells","volume":"9","author":"Qi","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"2021062208221218600_B81","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-019-01254-2","article-title":"Crizanlizumab: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"2021062208221218600_B82","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.061615598","article-title":"Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis","volume":"98","author":"Borsig","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2021062208221218600_B83","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1158\/0008-5472.CAN-05-3121","article-title":"L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest","volume":"66","author":"L\u00e4ubli","year":"2006","journal-title":"Cancer Res"},{"issue":"8","key":"2021062208221218600_B84","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00432-016-2131-6","article-title":"Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms","volume":"142","author":"Zhang","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2021062208221218600_B85","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021062208221218600_B86","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1055\/s-0040-1709712","article-title":"The efficacy and safety of low molecular weight heparin administration to improve survival of cancer patients: a systematic review and meta-analysis","volume":"120","author":"Montroy","year":"2020","journal-title":"Thromb Haemost"},{"issue":"3","key":"2021062208221218600_B87","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2021062208221218600_B88","first-page":"1600","article-title":"The effects of unfractionated heparin on survival in patients with malignancy\u2014a systematic review","volume":"82","author":"Smorenburg","year":"1999","journal-title":"Thromb Haemost"},{"issue":"6","key":"2021062208221218600_B89","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/phar.2409","article-title":"Systematic review of crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease","volume":"40","author":"Han","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2021062208221218600_B90","doi-asserted-by":"crossref","first-page":"102424","DOI":"10.1016\/j.bcmd.2020.102424","article-title":"Leukocyte adhesion to P-selectin and the inhibitory role of crizanlizumab in sickle cell disease: a standardized microfluidic assessment","volume":"83","author":"Man","year":"2020","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"2021062208221218600_B91","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/j.1538-7836.2005.01429.x","article-title":"GPVI and integrin alphaIIb beta3 signaling in platelets","volume":"3","author":"Watson","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2021062208221218600_B92","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1074\/mcp.M114.038513","article-title":"Copy number analysis of the murine platelet proteome spanning the complete abundance range","volume":"13","author":"Zeiler","year":"2014","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"2021062208221218600_B93","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/j.1538-7836.2006.01966.x","article-title":"von Willebrand factor mediates platelet spreading through glycoprotein Ib and alpha(IIb)beta3 in the presence of botrocetin and ristocetin, respectively","volume":"4","author":"McCarty","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2021062208221218600_B94","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1538-7836.2004.00925.x","article-title":"Evaluation of the role of platelet integrins in fibronectin-dependent spreading and adhesion","volume":"2","author":"McCarty","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2021062208221218600_B95","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0035-1564835","article-title":"Platelet physiology","volume":"42","author":"Gremmel","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2021062208221218600_B96","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1074\/jbc.M111.269811","article-title":"Engagement of \u03b1IIb\u03b23 (GPIIb\/IIIa) with \u03b1\u03bd\u03b23 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis","volume":"287","author":"Lonsdorf","year":"2012","journal-title":"J Biol Chem"},{"issue":"2","key":"2021062208221218600_B97","doi-asserted-by":"crossref","first-page":"C264","DOI":"10.1152\/ajpcell.00367.2018","article-title":"The role of coagulation and platelets in colon cancer-associated thrombosis","volume":"316","author":"Mitrugno","year":"2019","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"2021062208221218600_B98","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1055\/s-0038-1642691","article-title":"Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo","volume":"74","author":"Nierodzik","year":"1995","journal-title":"Thromb Haemost"},{"issue":"10","key":"2021062208221218600_B99","doi-asserted-by":"crossref","first-page":"C792","DOI":"10.1152\/ajpcell.00346.2014","article-title":"A physical sciences network characterization of circulating tumor cell aggregate transport","volume":"308","author":"King","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"2021062208221218600_B100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/(SICI)1097-0215(19970117)70:2<201::AID-IJC11>3.0.CO;2-L","article-title":"Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: involvement of platelet GPIIb-IIIa and tumor cell \u03b1(v) integrins","volume":"70","author":"Dardik","year":"1997","journal-title":"Int J Cancer"},{"issue":"10","key":"2021062208221218600_B101","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.271.10.5892","article-title":"Role of \u03b23 integrins in melanoma cell adhesion to activated platelets under flow","volume":"271","author":"Felding-Habermann","year":"1996","journal-title":"J Biol Chem"},{"issue":"8","key":"2021062208221218600_B102","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0002-9343(02)01146-4","article-title":"Oral glycoprotein IIb\/IIIa inhibition\u2014great idea, but it didn\u2019t work","volume":"112","author":"Cannon","year":"2002","journal-title":"Am J Med"},{"issue":"4","key":"2021062208221218600_B103","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.7150\/thno.29146","article-title":"Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases","volume":"9","author":"Yap","year":"2019","journal-title":"Theranostics"},{"issue":"2","key":"2021062208221218600_B104","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2005-05-1994","article-title":"A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2","volume":"107","author":"Suzuki-Inoue","year":"2006","journal-title":"Blood"},{"key":"2021062208221218600_B105","first-page":"1","article-title":"Roles of the CLEC-2-podoplanin interaction in tumor progression","volume":"4","author":"Suzuki-Inoue","year":"2018","journal-title":"Platelets"},{"issue":"1","key":"2021062208221218600_B106","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1172\/JCI122955","article-title":"Functional significance of the platelet immune receptors GPVI and CLEC-2","volume":"129","author":"Rayes","year":"2019","journal-title":"J Clin Invest"},{"issue":"3","key":"2021062208221218600_B107","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jth.13604","article-title":"C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice","volume":"15","author":"Shirai","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2021062208221218600_B108","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0037-1604090","article-title":"Platelet CLEC-2: roles beyond hemostasis","volume":"44","author":"Suzuki-Inoue","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"40","key":"2021062208221218600_B109","doi-asserted-by":"crossref","first-page":"42733","DOI":"10.18632\/oncotarget.5811","article-title":"Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"issue":"18","key":"2021062208221218600_B110","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1128\/JVI.00136-06","article-title":"DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets","volume":"80","author":"Chaipan","year":"2006","journal-title":"J Virol"},{"issue":"3","key":"2021062208221218600_B111","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1074\/mcp.D600007-MCP200","article-title":"A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein","volume":"6","author":"Senis","year":"2007","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"2021062208221218600_B112","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/s41467-017-02402-6","article-title":"The podoplanin-CLEC-2 axis inhibits inflammation in sepsis","volume":"8","author":"Rayes","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2021062208221218600_B113","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2019.218545","article-title":"Low dose Btk inhibitors selectively block platelet activation by CLEC-2","volume":"106","author":"Nicolson","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2021062208221218600_B114","doi-asserted-by":"crossref","first-page":"C373","DOI":"10.1152\/ajpcell.00325.2015","article-title":"Oral administration of Bruton\u2019s tyrosine kinase inhibitors impairs GPVI-mediated platelet function","volume":"310","author":"Rigg","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"2021062208221218600_B115","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41467-020-15584-3","article-title":"The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure","volume":"11","author":"Chauhan","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"2021062208221218600_B116","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2021062208221218600_B117","first-page":"1146","article-title":"Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3","volume":"135","author":"Mammadova-Bach","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2021062208221218600_B118","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3390\/ijms19082237","article-title":"Protease-activated receptor 1 as therapeutic target in breast, lung, and ovarian cancer: pepducin approach","volume":"19","author":"Covic","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"63","key":"2021062208221218600_B119","doi-asserted-by":"crossref","first-page":"107334","DOI":"10.18632\/oncotarget.21015","article-title":"Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2021062208221218600_B120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ajpath.2011.03.025","article-title":"Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer","volume":"179","author":"Cisowski","year":"2011","journal-title":"Am J Pathol"},{"issue":"3","key":"2021062208221218600_B121","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cell.2004.12.018","article-title":"PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells","volume":"120","author":"Boire","year":"2005","journal-title":"Cell"},{"issue":"15","key":"2021062208221218600_B122","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1158\/0008-5472.CAN-09-0187","article-title":"Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"issue":"62","key":"2021062208221218600_B123","doi-asserted-by":"crossref","first-page":"32010","DOI":"10.18632\/oncotarget.25880","article-title":"PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer","volume":"9","author":"Tekin","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2021062208221218600_B124","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1074248417708617","article-title":"Role for thrombin receptor antagonism with vorapaxar in secondary prevention of atherothrombotic events: from bench to bedside","volume":"23","author":"Moon","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"24","key":"2021062208221218600_B125","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1182\/blood-2012-06-438598","article-title":"Platelets increase the proliferation of ovarian cancer cells","volume":"120","author":"Cho","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2021062208221218600_B126","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood-2017-07-795898","article-title":"Ticagrelor breaks up the tumor-platelet party","volume":"130","author":"Mitrugno","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2021062208221218600_B127","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/cancers12010250","article-title":"Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells","volume":"12","author":"Elaskalani","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2021062208221218600_B128","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/cdd.2017.114","article-title":"ASK1 facilitates tumor metastasis through phosphorylation of an ADP receptor P2Y12 in platelets","volume":"24","author":"Kamiyama","year":"2017","journal-title":"Cell Death Differ"},{"issue":"9038","key":"2021062208221218600_B129","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"16","key":"2021062208221218600_B130","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2021062208221218600_B131","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"2021062208221218600_B132","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"2021062208221218600_B133","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archinternmed.2010.139","article-title":"Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance","volume":"170","author":"Kaul","year":"2010","journal-title":"Arch Intern Med"},{"issue":"12","key":"2021062208221218600_B134","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/archinternmed.2010.154","article-title":"Prasugrel as a potential cancer promoter: review of the unpublished data","volume":"170","author":"Floyd","year":"2010","journal-title":"Arch Intern Me"},{"issue":"4","key":"2021062208221218600_B135","first-page":"412","article-title":"Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome","volume":"37","author":"Roe","year":"2016","journal-title":"Eur Heart J"},{"key":"2021062208221218600_B136","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2018.12.014","article-title":"Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor","volume":"174","author":"Raposeiras-Roub\u00edn","year":"2019","journal-title":"Thromb Res"},{"issue":"2","key":"2021062208221218600_B137","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ehjcvp\/pvz003","article-title":"Is P2Y12 inhibitor therapy associated with an increased risk of cancer?","volume":"5","author":"Kaufmann","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"10","key":"2021062208221218600_B138","doi-asserted-by":"crossref","first-page":"e26125","DOI":"10.1371\/journal.pone.0026125","article-title":"Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells","volume":"6","author":"Egan","year":"2011","journal-title":"PLoS One"},{"issue":"659","key":"2021062208221218600_B139","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.3399\/bjgp17X691109","article-title":"Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data","volume":"67","author":"Bailey","year":"2017","journal-title":"Br J Gen Pract"},{"issue":"1","key":"2021062208221218600_B140","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1038\/s41598-018-25019-1","article-title":"A temporal examination of platelet counts as a predictor of prognosis in lung, prostate, and colon cancer patients","volume":"8","author":"Sylman","year":"2018","journal-title":"Sci Rep"},{"issue":"18","key":"2021062208221218600_B141","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJM199411033311807","article-title":"Chronic idiopathic thrombocytopenic purpura","volume":"331","author":"George","year":"1994","journal-title":"N Engl J Med"},{"issue":"20","key":"2021062208221218600_B142","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/bloodadvances.2019000250","article-title":"Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice","volume":"3","author":"Shirai","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2021062208221218600_B143","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/23\/3201\/1810517\/bloodbld2019003977c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/23\/3201\/1810517\/bloodbld2019003977c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:23:44Z","timestamp":1624335824000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/23\/3201\/475895\/Aspirin-and-antiplatelet-treatments-in-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":146,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,5,3]]},"published-print":{"date-parts":[[2021,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003977","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]}}}